乳腺MRI对比增强在可疑钼靶微钙化活检决策中的价值:一项前瞻性多中心研究
这项前瞻性多中心研究纳入444例筛查钼靶发现孤立可疑微钙化的女性,活检前行动态对比增强MRI(DCE-MRI),以钙化对应区域出现对比增强为MRI阳性。DCE-MRI对浸润癌全部检出,对DCIS检出58/66例(87.9%),假阴性率4.76%,敏感度95.2%、特异度40.2%、PPV 49.2%、NPV 93.3%;作者认为DCE-MRI可用于减少活检,代价是漏诊少数以低-中级别为主的DCIS。
要点
- DCE-MRI对钼靶可疑微钙化的敏感度为95.2%、NPV为93.3%,浸润癌全部检出。
- 66例DCIS中DCE-MRI检出58例(87.9%),假阴性8例中1例高级别、7例低-中级别。
- 若按MRI结果决定活检,本研究中有119例(26.8%)可避免活检。
核心结论
- 本研究中DCE-MRI检出全部浸润癌和除8例(12.1%)以外的全部DCIS,假阴性率4.76%。
- 作者认为DCE-MRI可用于决策流程以减少钼靶检出可疑钙化的活检数量,代价是漏诊少数以低-中级别为主的DCIS。
研究设计与样本
- 前瞻性多中心研究,纳入筛查钼靶发现孤立微钙化的444例女性,活检前行DCE-MRI并以钙化对应区域对比增强为MRI阳性。
- 由6名经验丰富的乳腺放射科医生评估图像并执行活检,记录影像表现与组织病理结果,以组织病理为参考计算MRI的敏感度、特异度、NPV和PPV。
关键影像表现/征象
- 325例(73.2%)在微钙化对应位置出现对比增强。
- DCE-MRI在全部102例浸润癌和66例DCIS中的58例(87.9%)为阳性。
- 8例DCIS出现MRI假阴性,其中1例为高级别,其余7例为低-中级别。
诊断标准与关键数值
- 以活检前DCE-MRI上钙化对应区域出现对比增强为MRI阳性发现。
- DCE-MRI对钼靶检出可疑微钙化的敏感度95.2%、特异度40.2%、PPV 49.2%、NPV 93.3%。
- DCE-MRI假阴性率为4.76%。
- 444例中276例(62.2%)病理诊断为良性,168例(37.8%)为恶性。
临床应用与阅片要点
- 作者认为DCE-MRI可用于决策流程以减少钼靶检出可疑钙化的活检数量,代价是漏诊少数以低-中级别为主的DCIS。
- 若本研究按MRI结果决定活检,119例(26.8%)将不进行活检。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To investigate the inclusion of breast MRI in radiological assessment of suspicious, isolated microcalcifications detected with mammography.
METHODS: In this prospective, multicenter study, cases with isolated microcalcifications in screening mammography were examined with dynamic contrast-enhanced MRI (DCE-MRI) before biopsy, and contrast enhancement of the relevant calcification localization was accepted as a positive finding on MRI. Six experienced breast radiologists evaluated the images and performed the biopsies. Imaging findings and histopathological results were recorded. Sensitivity, specificity, NPV, and PPV of breast MRI were calculated and compared with histopathological findings.
RESULTS: Suspicious microcalcifications, which were detected by screening mammograms of 444 women, were evaluated. Of these, 276 (62.2%) were diagnosed as benign and 168 (37.8%) as malignant. Contrast enhancement was present in microcalcification localization in 325 (73.2%) of the cases. DCE-MRI was positive in all 102 invasive carcinomas and in 58 (87.9%) of 66 DCIS cases. MRI resulted in false negatives in eight DCIS cases; one was high grade and the other seven were low-to-medium grade. The false-negative rate of DCE-MRI was 4.76%. The sensitivity, specificity, PPV, and NPV for DCE-MRI for mammography-detected suspicious microcalcifications were 95.2%, 40.2%, 49.2%, and 93.3%, respectively.
CONCLUSIONS: In this study, all invasive cancers and all DCIS except eight cases (12.1%) were detected with DCE-MRI. DCE-MRI can be used in the decision-making algorithm to decrease the number of biopsies in mammography-detected suspicious calcifications, with a tradeoff for overlooking a small number of DCIS cases that are of low-to-medium grade.
KEY POINTS: • All invasive cancer cases and 87.8% of all in situ cancer cases were detected with MRI, showing a low false-negative rate of 4.7%. • Dynamic contrast-enhanced MRI can be used in the decision-making algorithm to decrease the number of biopsies in mammography-detected suspicious calcifications, with a tradeoff for overlooking a small number of DCIS cases that are predominantly low-to-medium grade. • If a decision for biopsy were made based on MRI findings in mammography-detected microcalcifications in this study, biopsy would not be performed to 119 cases (26.8%).
引用
- Taskin F, Kalayci CB, Tuncbilek N, et al. The value of MRI contrast enhancement in biopsy decision of suspicious mammographic microcalcifications: a prospective multicenter study. Eur Radiol. 2020. PMID: 32939619. doi:10.1007/s00330-020-07265-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。